Forte Biosciences Inc
FBRX
Closed
$76.94
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 19 full-time employees. The company went IPO on 2017-04-13. The company is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The firm's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Key stats
Open
$76.88
Volume
2.01M
Market cap
$1.63B
Prev. close
$76.92
Impl / hst vl
-
Open interest
$0.00
$76.88
Day’s Range
$76.98
$15.51
52W Range
$77.20
Valuation
16
Valuation score
Strongly Overvalued
P/E
-
P/S
-
P/B
37.41
Current ratio
-
Debt / Equity
-
ROE
-
Gross margin
-
Income growth
5.40%
FCF growth
20.70
Analysts estimates
Consensus rating
Hold
The average rating from top 5 analysts indicates that stock may significantly underperform the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$75.28
The top 7 analysts forecasts that 12-month price may decrease by 2.16%, with a low of $61.61 and a high of $80.85
$61.61
Low
$75.28
Avg
$80.85
High
Current price
Earnings
Q2 ‘26 revenue
$0.00
Q2 ‘26 net income
-$23.33M
Revenue
Net income
Previous EPS
-$1.24
Estimate EPS
-$0.90
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply